Q-omics provides the consensus-scored TJP2 profile across patient tissues and cancer cell-line models. TJP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TJP2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TJP2 RNA expression shows 20,071 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where TJP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TJP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TJP2 survival associations across molecular data types. TJP2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TJP2 RNA expression–survival associations across cancer types. High TJP2 expression shows unfavorable associations in ACC and PAAD, but favorable associations in KIRC, UVM, LGG and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TJP2 RNA expression.
This table summarizes TJP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TJP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TJP2 shows lower tumor expression in KIRC, LUAD, BRCA, LUSC and KICH and higher tumor expression in COAD. The KIRC box plot shows higher TJP2 RNA expression in normal versus tumor tissue (log2 FC = −0.759, t-test p < 0.001).
This table shows molecular features associated with TJP2 in patient tissues and cancer cell lines. In patient samples, TJP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TJP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
